Creatine treatment in muscle disorders: a meta-analysis of randomised controlled trials
MAIN RESULTS In muscular dystrophies, analysis of pooled data of six trials revealed a significant improvement in maximum voluntary contraction (MVC) of about 8.5% with creatine supplementation compared with placebo ( fig 1 ). CONCLUSIONS There is evidence from randomised controlled trials that shor...
Gespeichert in:
| Veröffentlicht in: | Journal of neurology, neurosurgery and psychiatry neurosurgery and psychiatry, 2008-04, Vol.79 (4), p.366-367 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 367 |
|---|---|
| container_issue | 4 |
| container_start_page | 366 |
| container_title | Journal of neurology, neurosurgery and psychiatry |
| container_volume | 79 |
| creator | Kley, R A Tarnopolsky, M A Vorgerd, M |
| description | MAIN RESULTS In muscular dystrophies, analysis of pooled data of six trials revealed a significant improvement in maximum voluntary contraction (MVC) of about 8.5% with creatine supplementation compared with placebo ( fig 1 ). CONCLUSIONS There is evidence from randomised controlled trials that short and medium term creatine treatment improves muscle strength, increases lean body mass and is well tolerated in patients with muscular dystrophies. |
| doi_str_mv | 10.1136/jnnp.2007.127571 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70403447</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20514830</sourcerecordid><originalsourceid>FETCH-LOGICAL-b460t-93343314730a1bc071dc9d09f51c61178de09e91ca5e1f62042c36ebdfc780663</originalsourceid><addsrcrecordid>eNqFkcGL1TAQxoMo7nP17kkK4l6kz5kkTdq96UNdYVUQ9XkLaZJCnm36TFrY_e9N6WMFLzuXGZjfDN_MR8hzhC0iE28OIRy3FEBukcpK4gOyQS7qkjH49ZBsACgtGVRwRp6kdIAl6uYxOcOacc4a3JD9Ljo9-eCKaSkGF6bCh2KYk-ldYX0ao3UxXRa6GNykSx10f5t8KsauiDrYcfDJ2cKMYYpj3-dyil736Sl51OXknp3yOfnx4f333VV5_fXjp93b67LlAqayYYwzhlwy0NgakGhNY6HpKjQCUdbWQeMaNLpy2AkKnBomXGs7I2sQgp2Ti3XvMY5_ZpcmlQUZ1_c6uHFOSgKHfKu8F6RQIa8ZZPDlf-BhnGM-O6msBymnjagyBStl4phSdJ06Rj_oeKsQ1OKNWrxRizdq9SaPvDgtntvB2X8DJzMy8OoE6GR03-X_Gp_uOAoosWJ15sqV82lyN3d9HX8rIZms1JefO7Xff7769g65opl_vfLtcLhf5l_wb7MV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1781242965</pqid></control><display><type>article</type><title>Creatine treatment in muscle disorders: a meta-analysis of randomised controlled trials</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><creator>Kley, R A ; Tarnopolsky, M A ; Vorgerd, M</creator><creatorcontrib>Kley, R A ; Tarnopolsky, M A ; Vorgerd, M</creatorcontrib><description>MAIN RESULTS In muscular dystrophies, analysis of pooled data of six trials revealed a significant improvement in maximum voluntary contraction (MVC) of about 8.5% with creatine supplementation compared with placebo ( fig 1 ). CONCLUSIONS There is evidence from randomised controlled trials that short and medium term creatine treatment improves muscle strength, increases lean body mass and is well tolerated in patients with muscular dystrophies.</description><identifier>ISSN: 0022-3050</identifier><identifier>EISSN: 1468-330X</identifier><identifier>DOI: 10.1136/jnnp.2007.127571</identifier><identifier>PMID: 18344391</identifier><identifier>CODEN: JNNPAU</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Biological and medical sciences ; Child ; Child, Preschool ; Confidence intervals ; Creatine - administration & dosage ; Dose-Response Relationship, Drug ; Energy Metabolism - drug effects ; Female ; Glycogen Storage Disease Type V - diagnosis ; Glycogen Storage Disease Type V - drug therapy ; Glycogen Storage Disease Type V - genetics ; Hand Strength ; Humans ; Immunomodulators ; Long-Term Care ; Male ; Medical sciences ; Metabolism ; Middle Aged ; Muscle Strength - drug effects ; Muscular Atrophy - diagnosis ; Muscular Atrophy - drug therapy ; Muscular Atrophy - genetics ; Muscular Dystrophies - diagnosis ; Muscular Dystrophies - drug therapy ; Muscular Dystrophies - genetics ; Neurology ; Neuromuscular Diseases - diagnosis ; Neuromuscular Diseases - drug therapy ; Neuromuscular Diseases - genetics ; Pharmacology. Drug treatments ; Randomized Controlled Trials as Topic ; Registries ; Systematic review ; Treatment Outcome</subject><ispartof>Journal of neurology, neurosurgery and psychiatry, 2008-04, Vol.79 (4), p.366-367</ispartof><rights>2008 BMJ Publishing Group</rights><rights>2008 INIST-CNRS</rights><rights>Copyright: 2008 2008 BMJ Publishing Group</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b460t-93343314730a1bc071dc9d09f51c61178de09e91ca5e1f62042c36ebdfc780663</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jnnp.bmj.com/content/79/4/366.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttps://jnnp.bmj.com/content/79/4/366.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,778,782,3185,23558,27911,27912,77355,77386</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20171538$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18344391$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kley, R A</creatorcontrib><creatorcontrib>Tarnopolsky, M A</creatorcontrib><creatorcontrib>Vorgerd, M</creatorcontrib><title>Creatine treatment in muscle disorders: a meta-analysis of randomised controlled trials</title><title>Journal of neurology, neurosurgery and psychiatry</title><addtitle>J Neurol Neurosurg Psychiatry</addtitle><description>MAIN RESULTS In muscular dystrophies, analysis of pooled data of six trials revealed a significant improvement in maximum voluntary contraction (MVC) of about 8.5% with creatine supplementation compared with placebo ( fig 1 ). CONCLUSIONS There is evidence from randomised controlled trials that short and medium term creatine treatment improves muscle strength, increases lean body mass and is well tolerated in patients with muscular dystrophies.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Confidence intervals</subject><subject>Creatine - administration & dosage</subject><subject>Dose-Response Relationship, Drug</subject><subject>Energy Metabolism - drug effects</subject><subject>Female</subject><subject>Glycogen Storage Disease Type V - diagnosis</subject><subject>Glycogen Storage Disease Type V - drug therapy</subject><subject>Glycogen Storage Disease Type V - genetics</subject><subject>Hand Strength</subject><subject>Humans</subject><subject>Immunomodulators</subject><subject>Long-Term Care</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolism</subject><subject>Middle Aged</subject><subject>Muscle Strength - drug effects</subject><subject>Muscular Atrophy - diagnosis</subject><subject>Muscular Atrophy - drug therapy</subject><subject>Muscular Atrophy - genetics</subject><subject>Muscular Dystrophies - diagnosis</subject><subject>Muscular Dystrophies - drug therapy</subject><subject>Muscular Dystrophies - genetics</subject><subject>Neurology</subject><subject>Neuromuscular Diseases - diagnosis</subject><subject>Neuromuscular Diseases - drug therapy</subject><subject>Neuromuscular Diseases - genetics</subject><subject>Pharmacology. Drug treatments</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Registries</subject><subject>Systematic review</subject><subject>Treatment Outcome</subject><issn>0022-3050</issn><issn>1468-330X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkcGL1TAQxoMo7nP17kkK4l6kz5kkTdq96UNdYVUQ9XkLaZJCnm36TFrY_e9N6WMFLzuXGZjfDN_MR8hzhC0iE28OIRy3FEBukcpK4gOyQS7qkjH49ZBsACgtGVRwRp6kdIAl6uYxOcOacc4a3JD9Ljo9-eCKaSkGF6bCh2KYk-ldYX0ao3UxXRa6GNykSx10f5t8KsauiDrYcfDJ2cKMYYpj3-dyil736Sl51OXknp3yOfnx4f333VV5_fXjp93b67LlAqayYYwzhlwy0NgakGhNY6HpKjQCUdbWQeMaNLpy2AkKnBomXGs7I2sQgp2Ti3XvMY5_ZpcmlQUZ1_c6uHFOSgKHfKu8F6RQIa8ZZPDlf-BhnGM-O6msBymnjagyBStl4phSdJ06Rj_oeKsQ1OKNWrxRizdq9SaPvDgtntvB2X8DJzMy8OoE6GR03-X_Gp_uOAoosWJ15sqV82lyN3d9HX8rIZms1JefO7Xff7769g65opl_vfLtcLhf5l_wb7MV</recordid><startdate>20080401</startdate><enddate>20080401</enddate><creator>Kley, R A</creator><creator>Tarnopolsky, M A</creator><creator>Vorgerd, M</creator><general>BMJ Publishing Group Ltd</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20080401</creationdate><title>Creatine treatment in muscle disorders: a meta-analysis of randomised controlled trials</title><author>Kley, R A ; Tarnopolsky, M A ; Vorgerd, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b460t-93343314730a1bc071dc9d09f51c61178de09e91ca5e1f62042c36ebdfc780663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Confidence intervals</topic><topic>Creatine - administration & dosage</topic><topic>Dose-Response Relationship, Drug</topic><topic>Energy Metabolism - drug effects</topic><topic>Female</topic><topic>Glycogen Storage Disease Type V - diagnosis</topic><topic>Glycogen Storage Disease Type V - drug therapy</topic><topic>Glycogen Storage Disease Type V - genetics</topic><topic>Hand Strength</topic><topic>Humans</topic><topic>Immunomodulators</topic><topic>Long-Term Care</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolism</topic><topic>Middle Aged</topic><topic>Muscle Strength - drug effects</topic><topic>Muscular Atrophy - diagnosis</topic><topic>Muscular Atrophy - drug therapy</topic><topic>Muscular Atrophy - genetics</topic><topic>Muscular Dystrophies - diagnosis</topic><topic>Muscular Dystrophies - drug therapy</topic><topic>Muscular Dystrophies - genetics</topic><topic>Neurology</topic><topic>Neuromuscular Diseases - diagnosis</topic><topic>Neuromuscular Diseases - drug therapy</topic><topic>Neuromuscular Diseases - genetics</topic><topic>Pharmacology. Drug treatments</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Registries</topic><topic>Systematic review</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kley, R A</creatorcontrib><creatorcontrib>Tarnopolsky, M A</creatorcontrib><creatorcontrib>Vorgerd, M</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neurology, neurosurgery and psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kley, R A</au><au>Tarnopolsky, M A</au><au>Vorgerd, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Creatine treatment in muscle disorders: a meta-analysis of randomised controlled trials</atitle><jtitle>Journal of neurology, neurosurgery and psychiatry</jtitle><addtitle>J Neurol Neurosurg Psychiatry</addtitle><date>2008-04-01</date><risdate>2008</risdate><volume>79</volume><issue>4</issue><spage>366</spage><epage>367</epage><pages>366-367</pages><issn>0022-3050</issn><eissn>1468-330X</eissn><coden>JNNPAU</coden><abstract>MAIN RESULTS In muscular dystrophies, analysis of pooled data of six trials revealed a significant improvement in maximum voluntary contraction (MVC) of about 8.5% with creatine supplementation compared with placebo ( fig 1 ). CONCLUSIONS There is evidence from randomised controlled trials that short and medium term creatine treatment improves muscle strength, increases lean body mass and is well tolerated in patients with muscular dystrophies.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd</pub><pmid>18344391</pmid><doi>10.1136/jnnp.2007.127571</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3050 |
| ispartof | Journal of neurology, neurosurgery and psychiatry, 2008-04, Vol.79 (4), p.366-367 |
| issn | 0022-3050 1468-330X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70403447 |
| source | MEDLINE; BMJ Journals - NESLi2 |
| subjects | Adolescent Adult Aged Biological and medical sciences Child Child, Preschool Confidence intervals Creatine - administration & dosage Dose-Response Relationship, Drug Energy Metabolism - drug effects Female Glycogen Storage Disease Type V - diagnosis Glycogen Storage Disease Type V - drug therapy Glycogen Storage Disease Type V - genetics Hand Strength Humans Immunomodulators Long-Term Care Male Medical sciences Metabolism Middle Aged Muscle Strength - drug effects Muscular Atrophy - diagnosis Muscular Atrophy - drug therapy Muscular Atrophy - genetics Muscular Dystrophies - diagnosis Muscular Dystrophies - drug therapy Muscular Dystrophies - genetics Neurology Neuromuscular Diseases - diagnosis Neuromuscular Diseases - drug therapy Neuromuscular Diseases - genetics Pharmacology. Drug treatments Randomized Controlled Trials as Topic Registries Systematic review Treatment Outcome |
| title | Creatine treatment in muscle disorders: a meta-analysis of randomised controlled trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T22%3A33%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Creatine%20treatment%20in%20muscle%20disorders:%20a%20meta-analysis%20of%20randomised%20controlled%20trials&rft.jtitle=Journal%20of%20neurology,%20neurosurgery%20and%20psychiatry&rft.au=Kley,%20R%20A&rft.date=2008-04-01&rft.volume=79&rft.issue=4&rft.spage=366&rft.epage=367&rft.pages=366-367&rft.issn=0022-3050&rft.eissn=1468-330X&rft.coden=JNNPAU&rft_id=info:doi/10.1136/jnnp.2007.127571&rft_dat=%3Cproquest_cross%3E20514830%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1781242965&rft_id=info:pmid/18344391&rfr_iscdi=true |